Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-384 in mild-to-moderate Alzheimer's Disease
NCT01137526Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ABT-384 in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started May 2010; status: completed.
02
Drugs
ABT-384
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01137526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01137526.